NYSE:LLYPharmaceuticals
Eli Lilly Advances Oral GLP 1 And Immunology Growth Story
Eli Lilly (NYSE:LLY) reported that its oral GLP-1 candidate orforglipron outperformed Novo Nordisk’s oral semaglutide in a head to head Phase 3 trial in adults with type 2 diabetes.
The trial results showed superior blood sugar control and weight loss for orforglipron compared with the rival therapy.
The EMA’s Committee for Medicinal Products for Human Use issued a positive opinion to extend Olumiant’s use to adolescents with severe alopecia areata in Europe.
Eli Lilly is a large global...